HK Stock Market Move | JINHAI MED TECH (02225) surged more than 17% in the morning trading, the company partnered with China National Pharmaceutical Group Corporation to accelerate the commercialization process.

JINHAI MED TECH (02225) soared more than 17% in the morning session, rising 11.81% to HK$1.42 as of the time of writing, with a turnover of HK$2.3867 million. On the news front, on February 17, one of the largest professional media and service platforms in the medical equipment industry, "Qixiezhijia," released a list of the top ten innovative medical devices for 2025. JINHAI MED TECH's "4K3D naked-eye fluorescence endoscope camera system" was selected as one of the "Top Ten Endoscope Innovations for 2025." In addition, in early January of this year, JINHAI MED TECH announced that its subsidiary, Jinhai Xiehuan Medical, has authorized Guoyao Lingshang to be the exclusive distributor of the company's high-end medical equipment in China. It is reported that this signing of the commercial cooperation basically covers a basket of key products from today's medical care, including products such as the 4K3D fluorescence compound endoscope, foraminoscopy, and a series of advanced equipment sets. Public information shows that Guoyao Lingshang is a subsidiary of China Meheco Group, a joint venture between SINOPHARM Limited and Mitsubishi Corporation.